ETON — Eton Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1710340 ·
Last close
$64.43
Market Cap
$1.84B
52W High
$66.37
52W Low
$26.66
ADV30
667,063
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 24,266,000 | 14,735,000 | 2,414,000 | 1,554,000 | 97,710,000 | 19,661,000 | 67,095,000 |
| Dec 2025 | 21,281,000 | 13,100,000 | 2,464,000 | 1,483,000 | 92,114,000 | 25,942,000 | 65,960,000 |
| Sep 2025 | 22,459,000 | 7,855,000 | -1,363,000 | -1,927,000 | 104,510,000 | 37,121,000 | 81,384,000 |
| Jun 2025 | 18,928,000 | 11,924,000 | -1,475,000 | -2,585,000 | 101,676,000 | 25,379,000 | 77,715,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$15,839,000
Investing CF
$-15,408,000
Financing CF
$1,810,000
CapEx
$-23,256,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.07
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-110,940,000
Inventory
$14,467,000
Receivables
$13,408,000
ST Investments
—
EBIT TTM
$2,040,000
Pretax Income TTM
$-1,486,000
Interest Exp TTM
$3,504,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$105,595,000
EBITDA
$25,178,000
Free Cash Flow
$6,581,250
Enterprise Value
$1,816,551,552
Total Cash
$26,845,000
Total Debt
$29,225,000
Shares Out
28,583,135
Trailing EPS
$0.39
Book Value
$1.65
ROE
36.0%
ROA
11.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 79,950,000 | -844,000 | -4,601,000 | 92,114,000 | 65,960,000 | — | 10,524,000 |
| Dec 2024 | 39,011,000 | -2,597,000 | -3,823,000 | 76,123,000 | 51,695,000 | — | 969,000 |
| Dec 2023 | 31,642,000 | -1,192,000 | -936,000 | 31,740,000 | 16,263,000 | — | 6,815,000 |
| Dec 2022 | 21,251,000 | -8,260,000 | -9,021,000 | 25,030,000 | 11,952,000 | — | 4,821,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$2.58
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $40.00 · spot: $64.43 · call volume: 396 · put volume: 511Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DMRA | Damora Therapeutics, Inc. | $1.87B | $30.31 | — |
| HMDCF | HUTCHMED (China) Ltd | $1.88B | $2.16 | — |
| SEPN | Septerna, Inc. | $1.89B | $40.52 | — |
| SRPT | Sarepta Therapeutics, Inc. | $1.92B | $18.13 | — |
| GHRS | GH Research PLC | $1.93B | $28.10 | — |
News headlines (Yahoo Finance, 1h cache)
Three Biotech Stocks Stick Out With Their Stellar Charts
2026-08-21 16:09 · Yahoo
Eton Pharmaceuticals (ETON) Q2 2026 Earnings Call Transcript
2026-08-20 23:27 · Yahoo
Is Eton Pharmaceuticals (ETON) Fully Priced On Strong Q2 Results And Raised Guidance?
2026-08-15 04:20 · Yahoo
Why Eton Pharmaceuticals Is Top of the Class Today
2026-08-14 18:58 · Yahoo
This Analyst Believes Eton Pharma’s Raised Guidance Is ‘Conservative’ – ETON Stock Heads For Best Ever Day
2026-08-14 17:30 · Yahoo
Eton Pharmaceuticals Inc (ETON) (Q2 2026) Earnings Call Highlights: Record Revenue and ...
2026-08-14 05:02 · Yahoo
Eton Pharmaceuticals Q2 Earnings Call Highlights
2026-08-14 00:03 · Yahoo
Eton Pharmaceuticals, Inc. (ETON) Q2 Earnings and Revenues Beat Estimates
2026-08-13 22:05 · Yahoo
Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001
2026-08-05 10:50 · Yahoo
Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
2026-08-03 10:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.